Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial
R. B. Warren, J. M. Carrascosa, E. Fumero, A. Schoenenberger, M. G. Lebwohl, J. C. Szepietowski, K. Reich
Research output: Contribution to journal › Article › peer-review
19Scopus
citations
Fingerprint
Dive into the research topics of 'Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial'. Together they form a unique fingerprint.